Chapter 14: Vaccines – Principles, History, and Applications

Chapter 14: Vaccines

A Brief History of Vaccines

Vaccines are one of the most significant achievements in microbiology and public health. Their development has drastically reduced the burden of infectious diseases worldwide.

• Early Methods – Variolation: Practiced in China as early as the 10th century, variolation involved exposing healthy individuals to material from smallpox lesions to induce a mild infection and subsequent immunity. Mortality rates dropped from up to 30% (natural infection) to 1–2% (variolation).

• Edward Jenner’s Breakthrough (1796): Jenner observed that milkmaids exposed to cowpox did not contract smallpox. He inoculated a boy with cowpox, who then became immune to smallpox. This marked the birth of modern immunology and the term "vaccination" (from Latin vacca, cow).

• Louis Pasteur (late 1800s): Developed the rabies and anthrax vaccines, pioneered germ theory, and laid the foundation for modern microbiology and immunology.

• Modern Era: Vaccines now prevent over 25 infectious diseases, including smallpox, polio, measles, tetanus, hepatitis, and influenza. New vaccines continue to emerge for threats like COVID-19 and Ebola.

Vaccination: Effectiveness and Controversy

• Effectiveness: CDC estimates (1994–2013) show vaccines prevented 21 million hospitalizations and 732,000 deaths in the U.S. alone.

• Controversy: Public resistance has existed since the 1800s, often centered on government mandates, cultural beliefs, and debates over personal freedom versus public health.

• Modern Issues: The 1998 MMR/autism scandal (later retracted) led to decreased vaccination rates and outbreaks of preventable diseases. Large-scale studies have found no link between vaccines and autism.

Herd Immunity and Immunization Programs

Herd immunity occurs when a sufficient proportion of a population is immune to an infectious disease, reducing its spread and protecting non-immune individuals.

• Thresholds: Most pathogens require ~85% vaccination for herd immunity; highly contagious diseases like measles and pertussis require ~95%.

• Public Health: Immunization programs aim to achieve herd immunity, protecting the most vulnerable (e.g., infants, immunocompromised individuals).

• Vaccination Schedules: The CDC recommends routine childhood vaccines against more than 15 pathogens, with booster doses to optimize immune memory.

• Continued Need: Vaccines are recommended throughout life, including for adolescents (e.g., meningitis), pregnant women (Tdap), adults (influenza), and seniors (pneumonia, shingles).

Overview of Vaccines: Principles and Types

Vaccines induce artificially acquired active immunity, stimulating the adaptive immune system to develop memory B and T cells without causing disease.

• Immunity Development: Vaccines do not provide immediate protection; antibody levels peak about two weeks after administration.

• Formulations: Vaccines may contain attenuated microbes, inactivated pathogens, microbial fragments, inactivated toxins, or genetically engineered components.

• Risks: Routine vaccination risks are extremely low; some vaccines are not recommended for certain populations (e.g., pregnant women, immunocompromised individuals).

Types of Vaccines

Vaccines are categorized by how they are made and their components:

• Live Attenuated Vaccines: Contain weakened but live pathogens. Stimulate strong, long-lasting immunity but may not be suitable for immunocompromised individuals. Require refrigeration.

• Inactivated (Whole-Agent) Vaccines: Contain killed pathogens. Safe for immunocompromised patients, stable at room temperature, but may require boosters.

• Subunit Vaccines: Contain purified antigens or parts of the pathogen. Require adjuvants (e.g., aluminum salts, monophosphoryl lipid A) to enhance immune response. Types include:

  • Purified Subunit Vaccines: Only the immunogenic portion of the pathogen (e.g., recombinant vaccines).

  • Toxoid Vaccines: Contain inactivated toxins (e.g., tetanus, diphtheria).

  • Conjugate Vaccines: Polysaccharide antigens linked to proteins for enhanced immunogenicity.

• DNA Vaccines: Plasmids containing genes for antigens are injected; host cells produce the antigen, stimulating both humoral and cellular immunity.

• RNA Vaccines: mRNA encoding the antigen is delivered in lipid nanoparticles (e.g., some COVID-19 vaccines); host cells produce the antigen.

• Recombinant Vector Vaccines: Genetic material from the pathogen is inserted into a harmless virus or bacterium, which delivers the antigen gene to host cells, resulting in antigen production and immune response.

Key Vaccine Examples and Administration (Based on FDA Recommendations)

Vaccine	Administration	Formulation	Notes
COVID-19 vaccines	Injected	mRNA and vector formats	Protects against COVID-19 (SARS-CoV-2)
Diphtheria, tetanus, pertussis (DTaP, Tdap)	Intramuscular injection	Subunit/combination	Protects against diphtheria, tetanus, pertussis
Rabies vaccine	Intramuscular injection	Whole-agent inactivated	Post-exposure prophylaxis
Varicella-zoster virus vaccine	Subcutaneous injection	Live attenuated	Protects against chickenpox and shingles
Hepatitis A vaccine	Intramuscular injection	Whole-agent inactivated	Protects against hepatitis A
Hepatitis B vaccine	Intramuscular injection	Recombinant subunit	Protects against hepatitis B
HPV vaccine	Intramuscular injection	Recombinant	Protects against HPV and cancer
Influenza vaccine	Intramuscular or nasal	Whole-agent inactivated or live attenuated	Protects against influenza
Inactivated poliovirus vaccine (IPV)	Intramuscular injection	Whole-agent inactivated	Protects against poliovirus
MMR vaccine	Subcutaneous injection	Live attenuated	Protects against measles, mumps, rubella

Smallpox Eradication

• Smallpox is the only disease eradicated through vaccination (last natural case in 1977).

• Civilians are no longer vaccinated against smallpox, but concerns remain about its potential use as a bioterrorism agent.

Summary Table: Vaccine Types – Benefits and Drawbacks

Type	Benefits	Drawbacks
Live Attenuated	Strong, long-lasting immunity; broad protection	Risk for immunocompromised; requires refrigeration
Inactivated (Whole-Agent)	Safe for immunocompromised; stable	Weaker response; boosters needed
Subunit	Safe; targeted antigens	Requires adjuvants; boosters often needed
DNA/RNA	Stimulates both humoral and cellular immunity; rapid development	Still under study for long-term effects
Recombinant Vector	Strong immune response; flexible design	Complex production; pre-existing immunity to vector may reduce efficacy

Key Terms and Concepts

• Artificially Acquired Active Immunity: Immunity developed after exposure to a vaccine antigen.

• Adjuvant: Substance added to vaccines to enhance the immune response (e.g., aluminum salts).

• Herd Immunity: Protection of non-immune individuals when a critical portion of the population is immune.

• Booster: Additional vaccine dose to maintain or increase immunity.

Example: How Vaccines Work

• Example: The MMR vaccine (measles, mumps, rubella) is a live attenuated vaccine. After administration, the immune system develops memory cells specific to these viruses, providing long-term protection without causing disease.

Equations and Immunological Principles

• Basic Reproductive Number ($R_0$): The average number of secondary cases produced by a single infection in a susceptible population.

• Herd Immunity Threshold ($H$):

$H = 1 - \frac{1}{R_0}$

• Where $H$ is the proportion of the population that must be immune to prevent disease spread.

Additional info: These notes synthesize textbook content, lecture slides, and CDC recommendations to provide a comprehensive overview of vaccine principles, history, and applications in microbiology.